المؤلفون: Valeriy V. Breder, Liudmila G. Zhukova, Larisa V. Bolotina, Irina A. Demidova, Yaroslav A. Zhulikov, Elena V. Lubennikova, David R. Naskhletashvili, Sergey V. Orlov, Rashida V. Orlova, Ilya S. Romanov, Nikita A. Savelov, Ksenia A. Sarantseva, Alexandra S. Tyulyandina, Mikhail Yu. Fedyanin

المصدر: Современная онкология, Vol 25, Iss 3, Pp 295-300 (2023)

مصطلحات موضوعية: ntrk gene fusions, entrectinib, trk inhibitors, molecular testing in solid tumors, secretory carcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://modernonco.orscience.ru/1815-1434/article/viewFile/159394/pdfTest; https://doaj.org/toc/1815-1434Test; https://doaj.org/toc/1815-1442Test

الوصول الحر: https://doaj.org/article/c5b921b0ebf8481e8510cf935262712fTest

المؤلفون: Zhao X, Hao M, Zhang X, Wei J, Feng S, He Y, Jiang E, Han M

المصدر: OncoTargets and Therapy, Vol Volume 16, Pp 1055-1059 (2023)

مصطلحات موضوعية: entrectinib, acute myeloid leukemia, etv6::ntrk3, allogeneic hematopoietic stem cell transplantation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/post-hsct-maintenance-treatment-usingTest-entrectinib-for-an-aml-patient-a-peer-reviewed-fulltext-article-OTT; https://doaj.org/toc/1178-6930Test

الوصول الحر: https://doaj.org/article/b6ea861c87284beaaf3a9b03b7c36671Test

المؤلفون: Hiromune Sawada, Yuri Taniguchi, Shin Iizuka, Toshiki Ikeda, Masaharu Aga, Yusuke Hamakawa, Kazuhito Miyazaki, Yuki Misumi, Yoko Agemi, Yukiko Nakamura, Koki Maeda, Tsuneo Shimokawa, Hiroaki Okamoto

المصدر: Case Reports in Oncology, Vol 16, Iss 1, Pp 1558-1567 (2023)

مصطلحات موضوعية: entrectinib, ros1, crizotinib, leptomeningeal metastasis, non-small-cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://beta.karger.com/Article/FullText/534549Test; https://doaj.org/toc/1662-6575Test

الوصول الحر: https://doaj.org/article/97ef3a05d08549e587029f538dbb0f84Test

المؤلفون: Shaheenah Dawood, Zulfaqqar Jaffar Ali

المصدر: Case Reports in Oncology, Vol 16, Iss 1, Pp 1451-1459 (2023)

مصطلحات موضوعية: case report, metastatic melanoma, entrectinib, ntrk3 gene fusion, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://beta.karger.com/Article/FullText/534475Test; https://doaj.org/toc/1662-6575Test

الوصول الحر: https://doaj.org/article/d6ef7913c3d84b218d58bb78d3ec3999Test

المؤلفون: Dan Li, Yue Zhu, Jincheng Song, Dafu Yang, Saiqiong Cui, Xin Liu, Le Wang, Jiangyan Zhang, Evenki Pan, Zhaoxia Dai

المصدر: Frontiers in Oncology, Vol 14 (2024)

مصطلحات موضوعية: ALK rearrangement, brigatinib, entrectinib, resistance mutations, ETV6-NTRK3, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2024.1339511/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/86d94ff29ae34a21991f4c647c2ab4bbTest

المؤلفون: Kentaro Ito, Miho Nishio, Kentaro Fujiwara, Yoichi Nishii, Kengo Ushiro, Hiroki Yasui, Osamu Hataji

المصدر: Thoracic Cancer, Vol 14, Iss 25, Pp 2622-2626 (2023)

مصطلحات موضوعية: brain metastasis, entrectinib, ROS‐1 fusion, TP53 mutation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1759-7706Test; https://doaj.org/toc/1759-7714Test

الوصول الحر: https://doaj.org/article/c9e35c4ba19f4a5ab1b76c5ed0c10dfbTest

المؤلفون: Zhiwei Cui, Zhen Zhai, De Xie, Lihui Wang, Feiyan Cheng, Siyu Lou, Fan Zou, Rumeng Pan, Shixue Chang, Haoyan Yao, Jing She, Yidan Zhang, Xinyuan Yang

المصدر: Frontiers in Pharmacology, Vol 15 (2024)

مصطلحات موضوعية: NTRK, gene fusion, entrectinib, larotrectinib, FAERS, adverse drug event, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fphar.2024.1329409/fullTest; https://doaj.org/toc/1663-9812Test

الوصول الحر: https://doaj.org/article/f3a6c4fba82a49028ed33818ada829d9Test

المؤلفون: E. V. Reutova, K. K. Laktionov, Е. В. Реутова, К. К. Лактионов

المصدر: Meditsinskiy sovet = Medical Council; № 22 (2023); 57-62 ; Медицинский Совет; № 22 (2023); 57-62 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: энтректиниб, targeted therapy, NTRK1/2/3, ROS1 rearrangements, intracranial response, entrectinib, таргетная терапия, ROS1 перестройки, интракраниальный ответ

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7985/7072Test; Davare MA, Henderson JJ, Agarwal A, Wagner JP, Iyer SR, Shah N et al. Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma. Clin Cancer Res. 2018;24(24):6471–6482. https://doi.org/10.1158/1078-0432.CCR-18-1052Test.; Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, Lowe SW. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci USA. 2013;110(48):19513–19518. https://doi.org/10.1073/pnas.1311707110Test.; Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N et al. Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins. Cancer Res. 2019;79(3):546–556. https://doi.org/10.1158/0008-5472.CAN-18-1492Test.; Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18(17):4570–457. https://doi.org/10.1158/1078-0432.CCR-12-0550Test.; Davies KD, Doebele RC. Molecular pathways: ROS1 usion proteins in cancer. Clin Cancer Res. 2013;19(15):4040–4045. https://doi.org/10.1158/1078-0432.CCR-12-2851Test.; Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–870. https://doi.org/10.1200/JCO.2011.35.6345Test.; Dugay F, Llamas-Gutierrez F, Gournay M, Medane S, Mazet F, Chiforeanu DC et al. Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. Oncotarget. 2017;8(32):53336–53351. https://doi.org/10.18632/oncotarget.18408Test.; Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ et al. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1- Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2017;2017:PO.17.00063. https://doi.org/10.1200/PO.17.00063Test.; Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33(9):992–999. https://doi.org/10.1200/JCO.2014.58.3302Test.; Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, Hancock M et al. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol. 2018;13(11):1717–1726. https://doi.org/10.1016/j.jtho.2018.07.001Test.; Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T et al. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018;36(14):1405–1411. https://doi.org/10.1200/JCO.2017.75.5587Test.; Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121–1126. https://doi.org/10.1093/annonc/mdz131Test.; Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUROCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019;14(7):1266–1276. https://doi.org/10.1016/j.jtho.2019.03.020Test.; Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, Wilner KD. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):e443–445. https://doi.org/10.1200/JCO.2010.34.1313Test.; Jiang Q, Li M, Li H, Chen L. Entrectinib, a new multi-target inhibitor for cancer therapy. Biomed Pharmacother. 2022;150:112974. https://doi.org/10.1016/j.biopha.2022.112974Test.; Fischer H, Ullah M, de la Cruz CC, Hunsaker T, Senn C, Wirz T et al. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro Oncol. 2020;22(6):819–829. https://doi.org/10.1093/neuonc/noaa052Test.; Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R et al. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther. 2016;15(4):628–639. https://doi.org/10.1158/1535-7163.MCT-15-0758Test.; Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R et al. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. J Med Chem. 2016;59(7):3392–3408. https://doi.org/10.1021/acs.jmedchem.6b00064Test.; Iyer R, Wehrmann L, Golden RL, Naraparaju K, Croucher JL, MacFarland SP et al. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Lett. 2016;372(2):179–186. https://doi.org/10.1016/j.canlet.2016.01.018Test.; Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F et al. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Expert Opin Investig Drugs. 2015;24(11):1493–1500. https://doi.org/10.1517/13543784.2015.1096344Test.; Harada G, Santini FC, Wilhelm C, Drilon A. NTRK fusions in lung cancer: From biology to therapy. Lung Cancer. 2021;161:108–113. https://doi.org/10.1016/j.lungcan.2021.09.005Test.; Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):261–270. https://doi.org/10.1016/S1470-2045Test(19)30690-4.; Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC et al. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021;39(11):1253–1263. https://doi.org/10.1200/JCO.20.03025Test.; Drilon A, Chiu C-H, Fan Y, Cho BC, Lu S, Ahn M-J et al. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC. JTO Clin Res Rep. 2022;3(6):100332. https://doi.org/10.1016/j.jtocrr.2022.100332Test.; Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ et al. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol. 2017;35(23):2613–2618. https://doi.org/10.1200/JCO.2016.71.3701Test.; Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2019;20(12):1691–1701. https://doi.org/10.1016/S1470-2045Test(19)30655-2.; Doebele RC, Lin J, Nagasaka M, Baik C, Van Der Wekken A et al. MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors. J Thor Oncol. 2021;16(3):S174–175. https://doi.org/10.1016/j.jtho.2021.01.251Test.; Ou SI, Fujiwara Y, Shaw AT, Yamamoto N, Nakagawa K, Fan F et al. Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies. JTO Clin Res Rep. 2020;2(1):100108. https://doi.org/10.1016/j.jtocrr.2020.100108Test.; Rodrigus P, de Brouwer P, Raaymakers E. Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation. Lung Cancer. 2001;32(2):129–136. https://doi.org/10.1016/s0169-5002Test(00)00227-0.; Dziadziuszko R, Hung T, Wang K, Choeurng V, Drilon A, Doebele RC et al. Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib. Mol Oncol. 2022;16(10):2000–2014. https://doi.org/10.1002/1878-0261.13214Test.; Liu D, Flory J, Lin A, Offin M, Falcon CJ, Murciano-Goroff YR et al. Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann Oncol. 2020;31(9):1207–1215. https://doi.org/10.1016/j.annonc.2020.05.006Test.; Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019;30(Suppl. 8):viii23–viii30. https://doi.org/10.1093/annonc/mdz282Test.; Sartore-Bianchi A, Pizzutilo EG, Marrapese G, Tosi F, Cerea G, Siena S. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Expert Rev Anticancer Ther. 2020;20(5):333–341. https://doi.org/10.1080/14737140.2020.1747439Test.; Лактионов КК, Артамонова ЕВ, Бредер ВВ, Горбунова ВА, Демидова ИА, Деньгина НВ и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли. 2022;12(3s2-1):41–59. https://doi.org/10.18027/2224-5057-2022-12-3s2-41-59Test.; https://www.med-sovet.pro/jour/article/view/7985Test

الإتاحة: https://doi.org/10.21518/ms2023-421Test
https://doi.org/10.1158/1078-0432.CCR-18-1052Test
https://doi.org/10.1073/pnas.1311707110Test
https://doi.org/10.1158/0008-5472.CAN-18-1492Test
https://doi.org/10.1158/1078-0432.CCR-12-0550Test
https://doi.org/10.1158/1078-0432.CCR-12-2851Test
https://doi.org/10.1200/JCO.2011.35.6345Test
https://doi.org/10.18632/oncotarget.18408Test
https://doi.org/10.1200/PO.17.00063Test
https://doi.org/10.1200/JCO.2014.58.3302Test

المؤلفون: MAMATHA, PALANATI, D. V. R. N., BHIKSHAPATHI

المصدر: International Journal of Pharmacy and Pharmaceutical Sciences; Vol 16, Issue 2, 2024; 12-16 ; 0975-1491 ; 2656-0097

مصطلحات موضوعية: Pemigatinib, Entrectinib, Biliary tract cancer, Nanosponges, Cytotoxicity, Cell lines

وصف الملف: application/pdf; text/html

العلاقة: https://journals.innovareacademics.in/index.php/ijpps/article/view/49567/29536Test; https://journals.innovareacademics.in/index.php/ijpps/article/view/49567/29544Test; https://journals.innovareacademics.in/index.php/ijpps/article/view/49567Test

الإتاحة: https://journals.innovareacademics.in/index.php/ijpps/article/view/49567Test

المؤلفون: Patrício, João Pedro Vilar Miguel

المساهمون: Costa, Luís António Marques da, Mansinho, André Miguel Branco, Repositório da Universidade de Lisboa

مصطلحات موضوعية: Fusões de gene NTRK, Entrectinib, Larotrectinib, Prognóstico, Eficácia, Oncobiologia, Domínio/Área Científica::Ciências Médicas

وصف الملف: application/pdf

الإتاحة: http://hdl.handle.net/10451/63956Test